Here are six notes:
1. In 2004, Dr. Niklason founded Humacyte, a biotechnology and regenerative medicine company.
2. NAM is an independent organization composed of 2,000 health and medicine professionals as well as natural, social and behavioral science leaders.
3. Dr. Niklason was one of 70 members elected annually. Election is based on professional achievement and contribution to healthcare issues, as well as capability to offer resources and skills to NAM’s mission.
4. Dr. Niklason’s research culminated in the first investigational bioengineered human acellular vessel, called HUMACYL. It helps with End State Renal Disease.
5. A professor in New Haven, Conn.-based Yale University’s biomedical engineering and anesthesia department, Dr. Niklason received her medical degree from the University of Michigan in Ann Arbor.
6. She completed an anesthesia and intensive care unit medicine residency at the Massachusetts General Hospital in Boston.
“A distinguished researcher and scientist, Dr. Niklason is a clinician and innovator who is transforming a field of medicine and patient care,” said Carrie S. Cox, chairman and CEO, Humacyte.
Recent articles:
Drug company money pours in for Hillary Clinton, despite her tough stance on pharma: 4 things to know
Battle over ACA continues — Judge denies immediate appeal in House suit
Uninsured health fine to double in 2016: 5 things to know
